Profile for European Patent Office Patent: 2455382
✉ Email this page to a colleague
| Country | SPC | SPC Expiration |
|---|---|---|
| Lithuania | PA2017012 | ⤷ Start Trial |
| Netherlands | 300870 | ⤷ Start Trial |
| Germany | 122017000020 | ⤷ Start Trial |
| Denmark | CA 2017 00018 | ⤷ Start Trial |
| Denmark | CR 2017 00018 | ⤷ Start Trial |
| Luxembourg | LUC00016 | ⤷ Start Trial |
| France | 17C1013 | ⤷ Start Trial |
US Patent Family Members and Approved Drugs for European Patent Office Patent: 2455382
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| ⤷ Start Trial | Jun 12, 2027 | Incyte Corp | OPZELURA | ruxolitinib phosphate |
| ⤷ Start Trial | Jun 24, 2028 | Incyte Corp | OPZELURA | ruxolitinib phosphate |
| ⤷ Start Trial | Jun 24, 2028 | Incyte Corp | JAKAFI | ruxolitinib phosphate |
| ⤷ Start Trial | Jun 24, 2028 | Incyte Corp | OPZELURA | ruxolitinib phosphate |
| ⤷ Start Trial | Jun 24, 2028 | Incyte Corp | JAKAFI | ruxolitinib phosphate |
| ⤷ Start Trial | Jun 12, 2027 | Incyte Corp | OPZELURA | ruxolitinib phosphate |
| ⤷ Start Trial | Jun 12, 2027 | Incyte Corp | JAKAFI | ruxolitinib phosphate |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
